Ines Sanchez-Rivera, MD
Medical Oncology · El Paso, TXNPI 1508863408
Payments from drug & device makers
Across 681 payments — averaging $6309.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aadi Bioscience, Inc.$1.2M
- Genentech, Inc.$938K
- AstraZeneca$903K
- Eli Lilly$704K
- Takeda Pharmaceuticals U.S.A., Inc.$126K
- E.r. Squibb & Sons, L.L.C.$79K
- plus $339K from 26 others
Across 2 payments — averaging $2322.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Consulting fees$15,60669%
- Speaking & faculty fees$2,50011%
- Travel & lodging$1,6137%
- Food & beverage$2,38211%
- Education$3762%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aadi Bioscience, Inc. | 27 | $1,208,173 |
| Genentech, Inc. | 396 | $938,404 |
| AstraZeneca | 17 | $902,797 |
| Eli Lilly | 30 | $703,711 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $126,001 |
| E.r. Squibb & Sons, L.L.C. | 24 | $78,877 |
| Pfizer | 12 | $59,634 |
| Jazz Pharmaceuticals Inc. | 25 | $52,500 |
| F. Hoffmann-la Roche AG | 4 | $49,458 |
| Novartis | 9 | $45,217 |
| Merck | 6 | $34,875 |
| Sanofi US Services Inc. | 9 | $23,875 |
| G1 Therapeutics, Inc. | 8 | $17,214 |
| Veru Inc. | 6 | $15,868 |
| Novocure Inc. | 15 | $13,350 |
| Pharmacyclics LLC, An Abbvie Company | 37 | $10,298 |
| Stemline Therapeutics Inc. | 5 | $5,483 |
| Seagen Inc. | 2 | $4,063 |
| Sanofi | 1 | $2,108 |
| Janssen Research & Development, LLC | 3 | $1,158 |
| Partner Therapeutics, Inc. | 1 | $1,000 |
| Astrazeneca UK Limited | 1 | $1,000 |
| Genmab U.S., Inc. | 3 | $328 |
| Johnson & Johnson | 3 | $296 |
| Gilead(2 entities) | 4 | $242 |
| Genentech USA, Inc. | 2 | $197 |
| Regeneron Healthcare Solutions, Inc. | 2 | $139 |
| Bayer | 1 | $125 |
| AbbVie | 1 | $103 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| Beigene USA, Inc. | 1 | $81 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,296,691 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 63 | $1,169,244 |
| InlytaAxitinib | 48 | $972,380 |
| IbrancePalbociclib | 56 | $891,550 |
| TasignaNilotinib Hcl | 21 | $395,997 |
| CabometyxCabozantinib S-Malate | 13 | $333,569 |
| VerzenioAbemaciclib | 19 | $290,328 |
| LynparzaOlaparib | 19 | $257,501 |
| Lenalidomide | 13 | $196,535 |
| EliquisApixaban | 51 | $35,883 |
| XareltoRivaroxaban | 15 | $16,656 |
| Fondaparinux Sodium | 11 | $9,339 |
| Exemestane | 33 | $5,160 |
| Anastrozole | 371 | $4,592 |
| Dexamethasone | 61 | $1,181 |
| Letrozole | 46 | $838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Ibrance, Eliquis | $59,634 | $1,899,813155 claims |
| NovartisKisqali, Tasigna | $45,217 | $1,565,24284 claims |
| AstraZenecaLynparza | $902,797 | $257,50119 claims |
| Johnson & JohnsonXarelto | $296 | $16,65615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 495 medical oncology providers in Texas.
Other medical oncology in El Paso
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Sawsan RashdanDallas$29.9M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
- Sarina Piha PaulHouston$26M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.